Novo Nordisk Wegovy Showed Better Liver Data in Patient Group

MT Newswires Live11-09

Novo Nordisk (NVO) said Sunday that a post hoc review of its Phase 3 trial found Wegovy 2.4 mg outperformed placebo on liver tests in 106 adults with MASH and liver scarring who had a BMI below 27.

At week 72, liver enzyme levels dropped 39% for ALT and 33% for AST relative to placebo, while the fibrosis marker ELF improved and PRO-C3 fell 18%, the company said.

Novo said one measure of liver stiffness was not statistically significant.

The company described the post hoc findings as exploratory and hypothesis-generating, noting that further research is needed to assess their clinical significance.

Shares of the company were up 1.86% in Monday premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment